Charts

News

27 Nov, 2023
MENLO PARK, Calif., November 27, 2023--On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff’s belief that the Company is a "public shell," and that the continued listing of the Company’s securities is no longer warranted, and the Company’s non-compliance with certain board and committee composition listing
15 Aug, 2023
14:01
Seeking Alpha
14 Aug, 2023
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. (“Morphogenesis”), for an all-stock transaction to advan
05 Jun, 2023
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO
30 May, 2023
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annua
23 May, 2023
Privately-held Morphogenesis Inc has agreed to combine with CohBar Inc (NASDAQ: CWBR) in an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline. The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer. The combined company is expected to operate under the name "TuHURA Biosciences Inc" and to trade
Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and we
11 Nov, 2022
08 Nov, 2022
21:10
Seeking Alpha
22 Sep, 2022
15 Aug, 2022
16 May, 2022
20:07
Seeking Alpha
13 May, 2022
21:35
Seeking Alpha
29 Mar, 2022
15 Nov, 2021
21:14
Seeking Alpha
17 May, 2021
20:04
Seeking Alpha
27 Apr, 2021
30 Mar, 2021
20:05
Seeking Alpha

Related Articles